Go to content

Editoriale

Migliorare al ricerca no-profit

Dossier

Comitati etici al bivio: profit o no-profit?

Lettere alla redazione

Ultimo aggiornamento: 01 Febbraio 2012

Bibliografia dossier 1-2012

  1. Fabbri P et al. Manuale di dermatologia medica - Acne e rosacea; 2010; 6: 192-202. Elsevier-Masson editore.
  2. Bershad SV. In the clinic. Acne. Ann Intern Med 2008; 149: ITC1-1-ITC1-16.
  3. Spencer EH et al. Diet and acne: a review of the evidence. Int J Dermatol 2009; 48: 339-47.
  4. Smith EV et al. What’s new in acne? An analysis of systemic reviews published in 2009-2010. Clin Exp Dermatol 2011; 36: 119-22.
  5. Wolf R et al. Acne and diet. Clin Dermatol 2004;22: 387–93.
  6. Choi JM et al. A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatr Dermatol 2006; 23: 421-7.
  7. Acné: traiter sans médicament. Rev Prescr 2009; 29: 838-43.
  8. Stoll S et al. The effect of the menstrual cycle on acne. J Am Acad Dermatol 2001; 45: 957-60.
  9. Kaidbey KH et al. The pathogenesis of topical steroid acne. J Invest Dermatol 1974; 62: 31-6.
  10. Vhite GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998; 39: S34-7.
  11. Strauss JS et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007; 56: 651-63.
  12. Melnik B et al. Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. J Dtsch Dermatol Ges 2007; 5: 110-7.
  13. Downie M et al. Modelling the remission of individual acne lesions in vitro. Br J Dermatol. 2002; 147: 869-78.
  14. Magin P et al. A systematic review of the evidence for ‘myths and misconceptions’ in acne management: diet, face-washing and sunlight. Fam Pract; 2005: 62-70.
  15. Cordain L et al. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002; 138: 1584-90.
  16. Kaymak Y et al. Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne. J Am Acad Dermatol 2007; 57: 819-23.
  17. Enshaieh S et al. The efficacy of 5% topical tea tree oil gel in mild to moderate acne vulgaris: a randomized, double-blind placebo-controlled study. Indian J Dermatol Venereol Leprol 2007; 73: 22-5.
  18. Magin P et al. Topical and oral CAM in acne: a review of the empirical evidence and a consideration of its context. Complement Ther Med 2006; 14: 62-76. 
  19. Acne: no al fai da te. Salutest 2006; 63: 24-8.
  20. Acne: vere e false convinzioni. Informazione sui farmaci 2004. www.informazionisuifarmaci.it/database/fcr/sids.nsf/pagine/323025B3F96E4E65C1256F26003D58B0?OpenDocument (accesso del 19.01.2012).
  21. Goldman MP, Boyce SM. A single-center study of aminolevulinic acid and 417 NM photodynamic therapy in the treatment of moderate to severe acne vulgaris. J Drugs Dermatol 2003; 2: 393-6. 
  22. Ruiz-Esparza J, Gomez JB. Nonablative radiofrequency for active acne vulgaris: the use of deep dermal heat in the treatment of moderate to severe active acne vulgaris (thermotherapy): a report of 22 patients. Dermatol Surg 2003; 29: 333-9.   
  23. Patel N, Clement M. Selective nonablative treatment of acne scarring with 585 nm flashlamp pulsed dye laser. Dermatol Surg 2002; 28: 942-5. 
  24. Haedersdal M et al. Evidence-based review of lasers, light sources and photodynamic therapy in the treatment of acne vulgaris. J Eur Acad Dermatol Venereol 2008;  22: 267-78. 
  25. Hörfelt C. Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006; 155: 608-13. 
  26. Gold MH. Acne and PDT: new techniques with lasers and light sources. Lasers Med Sci 2007; 22: 67-72.
  27. Mayo Clinic. Acne treatments: Emerging therapies for clearer skin www.mayoclinic.com/health/acne-treatments/SN00038 (accesso del 19.01.2012). 
  28. Jensen BK et al. The negligible availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991; 24: 425-8. 
  29. Chen C et al: Negligible systemic absorption of topical isotretinoin cream: implications for teratogenicity. J Clin Pharmacol 1997; 37: 279-84.
  30. Belknap BS. Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis 1979; 23: 856–9.
  31. Shalita AR. Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis 1981; 28: 556– 8.
  32. Elstein W. Topical deodorized polysulfides. Broadscope acne therapy. Cutis 1981; 28: 468-72.
  33. Purdy S, de Berker D. Acne. BMJ 2006; 333: 949-53.
  34. Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: clinical evidence for adapalene 0.1% in combination therapies. J Drugs Dermatol 2006; 5: 785-94.
  35. Leyden JJ et al. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol 2001; 2: 33-9.
  36. Thiboutot DM et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9.
  37. Gollnick HP et al. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: 1180-9. 
  38. Eichenfield LE et al. Treatment of 2,453 acne vulgaris patients aged 12-17 years with the fixed-dose adapalene-benzoyl peroxide combination topical gel: efficacy and safety. J Drugs Dermatol 2010; 9: 1395-401.
  39. Arowojolu A et al. Combined oral contraceptives for the treatment of acne. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD004425. DOI: 10.1002/14651858.CD004425.pub4.
  40. Prescrire Rédaction. “etihinylestradiol + chlormadinone-Belara®. Nième association contraceptive orale, sans plus”. Rev Prescr 2006; 26: 570-71.
  41. Keri J, Shiman M. An update on the management of acne vulgaris. Clin Cosmet Investig Dermatol 2009; 2: 105-10.
  42. Etinilestradiolo/drospirenone. Aumento del rischio trombotico. Dialogo sui Farmaci 2011; 6: 256-7.
  43. Diane®. Riassunto delle Caratteristiche del Prodotto.
  44. Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. Am Acad Dermatol 2000; 43: 498-502.
  45. Isotretinoina orale in specialità o equivalenti. Riassunto delle Caratteristiche del Prodotto.
  46. Wysowski DK et al. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45: 515-9.
  47. National Institute for Health and Clinical Excellence (NICE). Referral advice. Acne. 2001. www.nice.org.uk/download.aspx?o=ReferralAdvice (accesso del 19.01.2012).
  48. Tan JK et al. Beliefs and perceptions of patients with acne. J Am Acad Dermatol 2001; 44: 439-45.
  49. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics 2006; 118: 1188-99. 
 

Sicurezza: restrizione delle indicazioni per nimesulide

17 Febbraio 2012

A causa di problematiche sulla sicurezza epatica e gastrointestinale correlate all'uso prolungato di nimesulide, il "trattamento sintomatico dell'osteoartrite dolorosa" non è più indicato.
leggi in comunicato AIFA

Lista di trasparenza

16 Febbraio 2012

E' disponibile l'aggiornamento del 15 febbraio 2012 della Lista di trasparenza con i prezzi di vendita al pubblico e la loro differenza con i prezzi di riferimento. Dei 4.617 farmaci generici compresi nella lista il 48% ha un prezzo al pubblico superiore a quello di riferimento, la differenza è a carico del paziente.

vai alla sezione

Comitati etici: appello

07 Febbraio 2012

Segnaliamo a tutti i lettori di Dialogo sui Farmaci una nota del Dott. Gianni Tognoni, Presidente del Comitato Etico di Trento, che sottolinea una novità potenzialmente dirompente, introdotta con l’art. 85 del Decreto Legge del 24 gennaio 2012 recante “Disposizioni urgenti per la concorrenza, lo sviluppo delle infrastrutture e la competitività”. 

leggi il resto

Crediti ECM

05 Febbraio 2012

Dialogo sui Farmaci attiva il nuovo servizio di Formazione a Distanza con 18 crediti ECM/anno

leggi la nostra proposta

Questionario per i lettori

03 Febbraio 2012

Anche quest’anno Dialogo sui Farmaci svolge un’indagine presso i propri abbonati per conoscere la loro opinione in merito ai prodotti e ai servizi che hanno acquistato. 
Entro il 29 febbraio 2012 puoi compilare il modulo direttamente sul sito internet. 
questionario